Marina Posts Lower Q2 Loss, Faces Cash Crunch by Year End | GenomeWeb

Marina Biotech last week reported a lower second-quarter net loss as research and development spending dropped and revenues increased.

The company also disclosed in a filing with the US Securities and Exchange Commission that its current resources are not sufficient to fund operations through the year and that it will need to raise money before then or revamp its drug-development plans.

For the three-month period ended June 30, Marina's net loss fell to $3.6 million, or $0.08 per share, versus a year-ago loss of $4.1 million, or $0.34 per share.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.